Hoppe CC - Search Results

1

Sickle cell disease: current treatment and emerging therapies.

Neumayr LD, Hoppe CC, Brown C. Neumayr LD, et al. Among authors: hoppe cc. Am J Manag Care. 2019 Nov;25(18 Suppl):S335-S343. Am J Manag Care. 2019. PMID: 31809007 Free article.

2

Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics Under Development.

Hoppe C, Neumayr L. Hoppe C, et al. Hematol Oncol Clin North Am. 2019 Jun;33(3):355-371. doi: 10.1016/j.hoc.2019.01.014. Epub 2019 Mar 28. Hematol Oncol Clin North Am. 2019. PMID: 31030807 Review.

3

Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: Single-institution experience.

Winstead M, Sun PP, Martin K, Earl J, Neumayr L, Hoppe C, Vichinsky E. Winstead M, et al. Pediatr Hematol Oncol. 2017 Mar;34(2):100-106. doi: 10.1080/08880018.2017.1313917. Epub 2017 May 22. Pediatr Hematol Oncol. 2017. PMID: 28532265 Clinical Trial.

4

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. Vichinsky E, et al. Among authors: hoppe cc. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. N Engl J Med. 2019. PMID: 31199090 Clinical Trial.

5

Novel therapies targeting the endothelium in sickle cell disease.

Hoppe CC. Hoppe CC. Hemoglobin. 2011;35(5-6):530-46. doi: 10.3109/03630269.2011.606482. Epub 2011 Sep 12. Hemoglobin. 2011. PMID: 21910600 Review.

6

How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.

Gardner K, Hoppe C, Mijovic A, Thein SL. Gardner K, et al. Br J Haematol. 2015 Sep;170(6):745-56. doi: 10.1111/bjh.13494. Epub 2015 May 13. Br J Haematol. 2015. PMID: 25967919 Free article. Review.

7

Inflammatory mediators of endothelial injury in sickle cell disease.

Hoppe CC. Hoppe CC. Hematol Oncol Clin North Am. 2014 Apr;28(2):265-86. doi: 10.1016/j.hoc.2013.11.006. Epub 2014 Jan 18. Hematol Oncol Clin North Am. 2014. PMID: 24589266 Review.

8

Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia.

Heath LE, Heeney MM, Hoppe CC, Adjei S, Agbenyega T, Badr M, Masera N, Zhou C, Brown PB, Jakubowski JA, Dampier C. Heath LE, et al. Among authors: hoppe cc. Clin Trials. 2017 Dec;14(6):563-571. doi: 10.1177/1740774517723307. Epub 2017 Jul 26. Clin Trials. 2017. PMID: 28743191 Clinical Trial.

9

Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.

Kanter J, Heath LE, Knorr J, Agbenyega ET, Colombatti R, Dampier C, Hassab H, Manwani D, Robitaille N, Brown PB, Jakubowski JA, Yao S, Hoppe C. Kanter J, et al. Br J Haematol. 2019 Mar;184(6):1058-1061. doi: 10.1111/bjh.15250. Epub 2018 Apr 20. Br J Haematol. 2019. PMID: 29676449 Free article. No abstract available.

10

Potential role for statins in sickle cell disease.

Adam SS, Hoppe C. Adam SS, et al. Pediatr Blood Cancer. 2013 Apr;60(4):550-7. doi: 10.1002/pbc.24443. Epub 2012 Dec 31. Pediatr Blood Cancer. 2013. PMID: 23281161 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page